

Q Use a keyword, test name or number

## ASH FibroSure®

**TEST: 550180** 

CPT: [MAAA: 0002M] or 82172; 82247; 82465; 82947; 82977; 83010; 83883; 84450;

84460; 84478

Synonyms

- Alcoholic Liver Disease
- Noninvasive Liver Biopsy
- Steatohepatitis

Special Instructions The patient's age, gender, height, and weight at the time of collection must be submitted for FibroSure® testing.

Expected

3 - 6 days

Turnaround

Time

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Related

Hepatitis C Virus (HCV) FibroSure®

Information

• NASH FibroSure®

Related

Sample Report

**Documents** 

## SPECIMEN REQUIREMENTS

Specimen

Serum

Volume

3.5 mL

Minimum

2 mL

Volume

Container	Red-top tube or gel-barrier tube
Collection	Separate serum from cells within two hours of collection.
Storage	Specimen can be stored refrigerated at 2°C to 8°C for 72 hours and frozen at -70°C for seven
Instructions	days. Frozen samples are stable for one freeze/thaw cycle.
Patient Preparation	Patient should be <b>fasting</b> for at least eight hours.
Causes for Rejection	Gross hemolysis; gross lipemia; improper labeling; nonfasting specimen; patient <b>younger than</b> 14 years of age
TEST DETAILS	
Use	This test is intended for noninvasive assessment of liver status in patients with alcoholic liver
	disease. Quantitative results of 10 biochemicals in combination with age, gender, height, and
	weight are analyzed using a computational algorithm to provide a quantitative surrogate
	marker (0.0-1.0) of liver fibrosis (Metavir F0-F4), hepatic steatosis (0.0-1.0, S0-S3), and
	alcoholic steatohepatitis (ASH) (0.0-1.0, H0-H3).
Limitations	ASH FibroSure® is recommended for patients with suspected alcoholic liver disease. It is not
	recommended for patients with other liver diseases. It is also not recommended in patients
	with Gilbert disease, acute hemolysis, acute hepatitis, acute inflammation of the liver,
	extrahepatic cholestasis, transplant patients, and/or renal insufficiency patients. Any of these
	clinical situations may lead to inaccurate quantitative predictions of fibrosis.
	This test was developed, and its performance characteristics determined, by LabCorp. It has
	not been cleared or approved by the US Food and Drug Administration (FDA). The FDA has
	determined that such clearance or approval is not necessary.
References	Naveau S, Raynard B, Ratziu V, et al. Biomarkers for the prediction of liver fibrosis in patients
	with chronic alcoholic liver disease. <i>Clin Gastroenterol Hepatol</i> . 2005 Feb; 3(2):167-174.
	PubMed 15704051
	Poynard T, Ratziu V, Naveau S, et al. The diagnostic value of biomarkers (SteatoTest) for the
	prediction of liver steatosis. Comp Hepatol. 2005 Dec 23; 4:10. PubMed 16375767
	Thabut D, Naveau S, Charlotte F, et al. The diagnostic value of biomarkers (AshTest) for the
	prediction of alcoholic steatohepatitis in patients with chronic alcoholic liver disease. <i>J</i>
	<i>Hepatol.</i> 2006 Jun; 44(6):1175-1185. <u>PubMed 16580087</u>

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

## CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at <a href="https://loinc.org/license/">https://loinc.org/license/</a>. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf

Privacy Statement Terms of Use Notice of Nondiscrimination

Combatting Modern Slavery and Human Trafficking Statement

© 2022 Laboratory Corporation of America® Holdings. All Rights Reserved.